A 64-Year-Old-Man with Metastatic Prostate Cancer

Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer, reviews the potential treatment options, including PARP inhibitors, and highlights the importance of genetic testing when selecting treatment regimens.

EP1: Case Presentation: A 64-Year-Old Man with Metastatic Prostate Cancer

May 23rd 2022

Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer and a BRCA2 mutation.

EP2: Typical Presentations of Metastatic Prostate Cancer and Risk of Disease Progression

May 23rd 2022

Dr Neal Shore gives his first impressions of a patient case and gauges the risk of progression.

EP3: The Utility of Genetic Testing in Patients with Prostate Cancer

May 23rd 2022

An expert urologist highlights the vital importance of genetic testing in cases of prostate cancer.

EP4: Mutations in HRR-Related Genes in Prostate Cancer

May 23rd 2022

A focused discussion on the significance of mutations in homologous recombination repair (HRR)-related genes in prostate cancer.

EP5: Available Treatment Options for Chemotherapy-Naïve mCRPC

May 23rd 2022

Neal Shore, MD, explains the available first-line treatment options for chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC).

EP6: Olaparib Safety and Efficacy Data from the PROfound Trial

May 23rd 2022

An overview of safety and efficacy data from the phase 3 PROfound trial evaluating the PARP inhibitor olaparib.

EP7: A Urologist’s Treatment Selection for Metastatic Prostate Cancer

May 23rd 2022

Dr Neal Shore shares how he would have treated the patient with metastatic prostate cancer from the presented case.

EP8: Potential Use of PARP Inhibitors for First-Line Treatment of mCRPC

May 23rd 2022

A review of whether PARP inhibitors such as olaparib could potentially be used in earlier lines of therapy for mCRPC.

EP9: Current Challenges and Future Directions in Metastatic Prostate Cancer

May 23rd 2022

Neal Shore, MD, FACS, muses about the unmet needs in metastatic prostate cancer treatment and shares clinical pearls for community oncologists.